

Hikma opens new UK office to support NHS supply, strengthening European presence

London, 3 June 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announced the official opening of its commercial office in the UK, Hikma Pharmaceuticals International Limited (Hikma UK). Hikma will now directly supply NHS hospitals with injectable medicines across a broad range of therapeutic areas, reinforcing Hikma's long-standing commitment to the NHS.

Over the past eight years, Hikma has established itself as a trusted partner and critical supplier of injectable medicines to the NHS through a third-party partnership. Following the opening of this new commercial office, Hikma UK will now supply medicines to hospitals directly, leveraging its manufacturing facilities in Portugal, Italy, and Germany.

To date, Hikma has received 49 approvals and has launched 30 products (INN)¹ in the UK.

Dr Bill Larkins, President of Hikma Injectables commented:

“The opening of the UK office, following our entry into Spain in May, is another significant milestone in our global strategy to expand our footprint across Europe. Our local presence, with manufacturing facilities in Portugal, Italy, and Germany, reduces supply chain complexities and enables us to provide NHS hospitals with direct and rapid access to essential injectable medicines.”

Daniel Green, Director, Commercial - UK and North Europe added:

“I'm excited to lead Hikma's dedicated commercial office in the UK. This demonstrates our ongoing commitment to supporting healthcare systems, including the NHS, by ensuring reliable access to high-quality and affordable injectable medicines.”

The Hikma UK Ltd office is co-located with the Hikma PLC office in London. For more information about Hikma UK, please go to <https://www.hikma.com/en-uk/overview/>.

-- ENDS --

Enquiries:

Hikma (Investors)

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 (0)7776 477050
Guy Featherstone Director, Investor Relations	+44 (0)20 3892 4389/ +44 (0)7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 (0)7970 709912

Teneo (Press)

Doug Campbell / Rob Yates	+44 (0)7753 136628/ +44 (0)7715 375443
---------------------------	--

1. INN. name used to identify the active ingredient in a medicine. <https://www.ema.europa.eu/en/glossary/international-non-proprietary-name>



About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.